Vincristine is a neurotoxic, antineoplastic drug of the vinca alkaloid group.
Accidental administration of vincristine via the intrathecal route almost always results in central nervous system dysfunction and death.
The Vincristine Standard of the NSW Health High-Risk Medicines Management Policy (PD2020_045) outlines the minimum actions required to prevent accidental intrathecal administration of vincristine. The Vincristine Standard includes a risk mitigation strategy and addresses vincristine storage, supply and administration.
The tool below can also be used to assist hospitals in monitoring risks associated with vincristine. It can also be used to monitor local implementation and compliance with the Vincristine Standard of the High-Risk Medicines Management Policy.